HROW vs UNH

Harrow Inc. (HROW) remains a high-risk, high-reward investment focused on consolidating the fragmented ophthalmic market. The long-term strategic vision through M&A and specialized distribution holds significant 10x potential, underpinned by a large total addressable market. The previous catalyst of a permanent J-Code for IOPIDINE 1% remains supportive. However, financial risks persist with ongoin...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...